Floatz logo

Durvalumab

Appendiceal Cancer

Ludwig Institute for Cancer Researchmonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Appendiceal Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2B
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
Nilotinib
National Cancer Institute (NCI)
Phase 2B
Evomela
University of Kansas Medical Center
Phase 2CCC

View all 26 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →